Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Open Day and advance notice of AGM
Manchester, UK – 16 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be hosting an Open Day at its new facilities on Manchester Science Park, Manchester, UK on Tuesday 27 September 2022 from 3pm to 6pm, welcoming shareholders, analysts and other interested stakeholders.
The Open Day will follow immediately after the Company’s Annual General Meeting (“AGM”) which will be held from 2pm-3pm on the same day. The formal Notice of Meeting for the AGM will be issued shortly and confirmed by separate announcement.
The Open Day will provide an opportunity to meet the Senior Management team, take a tour of the Company’s new facilities and laboratories and familiarise themselves with the Company’s genomic technology and service solutions.
All Open Day attendees must register through Walbrook PR to reserve a space. For more information and to register, please email firstname.lastname@example.org or telephone Walbrook PR on +44 (0)20 7933 8780.
Participation protocols for the AGM will be provided to shareholders and notified separately in due course, but Open Day attendees can also provide advance notice of AGM attendance to Walbrook when they register for the Open Day.
As previously indicated in the Audited Final Results release dated 27 July 2022, an electronic copy of the Company’s Annual Report and Accounts for the financial year ended 31 March 2022 is available online at https://www.yourgene-health.com/investors/key-documents/financial-reports
The Directors of the Company take responsibility for this announcement.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Cairn Financial Advisers LLP (NOMAD)|
Liam Murray / James Caithie / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|Singer Capital Markets (Joint Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Walbrook PR Ltd (Media and Investor Relations)
Lianne Applegarth / Alice Woodings
Tel: +44 (0)20 7933 8780 or email@example.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The Yourgene Genomic Services team works with healthcare professionals, researchers and pharmaceutical organisations to support and accelerate scientific advances in genomic medicine. The division’s specialist services guide decisions about abnormalities, hereditary risk and treatment in addition to providing novel insights in research and discovery. Accredited clinical services are provided in Oncology and Reproductive Health within the UK and worldwide. The team of scientific experts offer consultative services to help guide partners in selecting the right technology and approach for their applications.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.